CY1123417T1 - Παραγωγα τετρα�δροϊσοκινολινης - Google Patents
Παραγωγα τετρα�δροϊσοκινολινηςInfo
- Publication number
- CY1123417T1 CY1123417T1 CY20201100923T CY201100923T CY1123417T1 CY 1123417 T1 CY1123417 T1 CY 1123417T1 CY 20201100923 T CY20201100923 T CY 20201100923T CY 201100923 T CY201100923 T CY 201100923T CY 1123417 T1 CY1123417 T1 CY 1123417T1
- Authority
- CY
- Cyprus
- Prior art keywords
- droisoquinoline
- tetra
- derivatives
- diseases
- role
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188174 | 2014-10-08 | ||
| PCT/EP2015/073053 WO2016055479A1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123417T1 true CY1123417T1 (el) | 2021-12-31 |
Family
ID=51790569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100923T CY1123417T1 (el) | 2014-10-08 | 2020-09-30 | Παραγωγα τετρα�δροϊσοκινολινης |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10105359B2 (enExample) |
| EP (1) | EP3204359B1 (enExample) |
| JP (1) | JP6622299B2 (enExample) |
| CN (1) | CN107001278B (enExample) |
| BR (1) | BR112017007123B1 (enExample) |
| CA (1) | CA2963951C (enExample) |
| CY (1) | CY1123417T1 (enExample) |
| DK (1) | DK3204359T3 (enExample) |
| EA (1) | EA035544B1 (enExample) |
| ES (1) | ES2821821T3 (enExample) |
| HR (1) | HRP20201469T1 (enExample) |
| HU (1) | HUE050664T2 (enExample) |
| LT (1) | LT3204359T (enExample) |
| PL (1) | PL3204359T3 (enExample) |
| PT (1) | PT3204359T (enExample) |
| RS (1) | RS60933B1 (enExample) |
| SI (1) | SI3204359T1 (enExample) |
| WO (1) | WO2016055479A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108884077A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| CN108884050B (zh) | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| CN107698433A (zh) * | 2017-09-12 | 2018-02-16 | 潍坊滨海石油化工有限公司 | 苯乙酸的制备方法 |
| ES2899679T3 (es) | 2017-12-01 | 2022-03-14 | UCB Biopharma SRL | Agentes de formación de imágenes |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| MX2021015872A (es) * | 2019-07-01 | 2022-02-03 | UCB Biopharma SRL | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. |
| PH12021552825A1 (en) * | 2019-07-01 | 2022-10-03 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| US20230255934A1 (en) * | 2020-04-24 | 2023-08-17 | The Regents Of The University Of California | Nurr1 receptor modulators and uses thereof |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| EP4200280B1 (en) * | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| EP4267555A1 (en) | 2020-12-03 | 2023-11-01 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| ES3004257T3 (en) * | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| CA3202106A1 (en) | 2020-12-18 | 2022-06-23 | Adrian Hall | Dihydroisoquinolinyl derivatives |
| CN116685308A (zh) * | 2020-12-18 | 2023-09-01 | Ucb生物制药有限责任公司 | 无定形固体分散体 |
| SI4263517T1 (sl) * | 2020-12-18 | 2025-01-31 | UCB Biopharma SRL | Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1 |
| US20240299375A1 (en) | 2021-03-08 | 2024-09-12 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| CN117337173A (zh) | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
| CN114671810B (zh) * | 2022-03-21 | 2024-03-22 | 济南鸿湾生物技术有限公司 | 一种咪唑苯脲的制备方法 |
| CN115611768B (zh) * | 2022-11-14 | 2024-03-05 | 郑州大学 | 一种3,4-二氯苯腈的合成方法 |
| CN118724764B (zh) * | 2024-06-07 | 2025-11-18 | 绍兴文理学院 | 一种芳基伯磺酰胺类化合物的制备方法 |
| CN119569653B (zh) * | 2024-11-25 | 2026-04-14 | 滁州市庆云医药有限公司 | 一种罗沙司他中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766131A (en) * | 1980-10-17 | 1988-08-23 | Pennwalt Corporation | 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics |
| AU2002351733A1 (en) * | 2001-12-19 | 2003-06-30 | H. Lundbeck A/S | 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| ES2342083T3 (es) * | 2004-04-29 | 2010-07-01 | Aventis Pharmaceuticals Inc. | 3-piperidinilisocroman-5-oles como agonistas de dopamina. |
| JP2010520217A (ja) * | 2007-03-01 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物 |
-
2015
- 2015-10-06 EA EA201790785A patent/EA035544B1/ru not_active IP Right Cessation
- 2015-10-06 CN CN201580064005.3A patent/CN107001278B/zh not_active Expired - Fee Related
- 2015-10-06 WO PCT/EP2015/073053 patent/WO2016055479A1/en not_active Ceased
- 2015-10-06 PT PT157756883T patent/PT3204359T/pt unknown
- 2015-10-06 DK DK15775688.3T patent/DK3204359T3/da active
- 2015-10-06 JP JP2017518989A patent/JP6622299B2/ja active Active
- 2015-10-06 PL PL15775688.3T patent/PL3204359T3/pl unknown
- 2015-10-06 ES ES15775688T patent/ES2821821T3/es active Active
- 2015-10-06 CA CA2963951A patent/CA2963951C/en active Active
- 2015-10-06 EP EP15775688.3A patent/EP3204359B1/en active Active
- 2015-10-06 US US15/517,795 patent/US10105359B2/en active Active
- 2015-10-06 HU HUE15775688A patent/HUE050664T2/hu unknown
- 2015-10-06 RS RS20201139A patent/RS60933B1/sr unknown
- 2015-10-06 BR BR112017007123-1A patent/BR112017007123B1/pt not_active IP Right Cessation
- 2015-10-06 HR HRP20201469TT patent/HRP20201469T1/hr unknown
- 2015-10-06 LT LTEP15775688.3T patent/LT3204359T/lt unknown
- 2015-10-06 SI SI201531348T patent/SI3204359T1/sl unknown
-
2020
- 2020-09-30 CY CY20201100923T patent/CY1123417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3204359T (pt) | 2020-09-24 |
| US10105359B2 (en) | 2018-10-23 |
| EA035544B1 (ru) | 2020-07-03 |
| JP6622299B2 (ja) | 2019-12-18 |
| BR112017007123B1 (pt) | 2023-01-31 |
| EA201790785A1 (ru) | 2017-10-31 |
| HRP20201469T1 (hr) | 2020-12-11 |
| HUE050664T2 (hu) | 2020-12-28 |
| DK3204359T3 (da) | 2020-09-14 |
| EP3204359A1 (en) | 2017-08-16 |
| EP3204359B1 (en) | 2020-07-01 |
| CA2963951A1 (en) | 2016-04-14 |
| RS60933B1 (sr) | 2020-11-30 |
| CN107001278A (zh) | 2017-08-01 |
| LT3204359T (lt) | 2020-10-12 |
| PL3204359T3 (pl) | 2021-03-22 |
| JP2017530185A (ja) | 2017-10-12 |
| BR112017007123A2 (pt) | 2017-12-19 |
| CN107001278B (zh) | 2020-11-24 |
| ES2821821T3 (es) | 2021-04-27 |
| WO2016055479A1 (en) | 2016-04-14 |
| US20170304292A1 (en) | 2017-10-26 |
| CA2963951C (en) | 2023-02-28 |
| SI3204359T1 (sl) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1125230T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
| CY1123633T1 (el) | Ετεροκυκλικες ενωσεις και οι χρησεις αυτων | |
| CY1122415T1 (el) | Κυκλοπροπυλαμινες ως lsd1 αναστολεις | |
| EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
| CY1118869T1 (el) | Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| CY1124682T1 (el) | Ανταγωνιστες toy trpv4 | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| CY1120864T1 (el) | Ενωσεις πυραζολης και η χρηση τους ως αναστολεις διαυλων ασβεστιου τυπου τ | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| CY1119489T1 (el) | Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| CY1122196T1 (el) | Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων | |
| CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| CY1123744T1 (el) | Παραγωγα πυριδινυλιου, φαρμακευτικες συνθεσεις και χρησεις αυτων ως αναστολεων aoc3 |